Stockreport

New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

Immuron Limited - American Depositary Shares  (IMRN) 
US:NASDAQ Investor Relations: immuron.com/investor-centre/business-overview
PDF Key Highlights: AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic targeting Camp [Read more]